Clinical Outcomes of Ileostomy Closure during versus after Adjuvant Chemotherapy in Patients with Rectal Cancer
Table 1
Comparison of demographic characteristics between two groups.
Group A
Group B
value
(n = 115) (%)
(n = 100) (%)
Sex, male
73 (63.5%)
61 (61.0%)
0.708
Age (year)
61.43 ± 10.66
59.77 ± 10.74
0.259
BMI (kg/m2)
22.87 ± 3.185
23.33 ± 2.91
0.274
Smoking
46 (40.0%)
48 (48.0%)
0.238
Alcohol consumption
44 (34.8%)
44 (44.0%)
0.393
Comorbidity
Hypertension
26 (22.6%)
23 (23.0%)
0.946
Diabetes
16 (13.9%)
8 (8.0%)
0.170
Coronary disease
14 (12.2%)
11 (11.0%)
0.789
Pneumonia
6 (5.2%)
9 (9.0%)
0.278
Hepatitis
3 (2.6%)
8 (8.0%)
0.118
ASA score
0.668
I
37 (32.2%)
38 (38.0%)
II
51 (44.3%)
41 (41.0%)
III
27 (23.5%)
21 (21.0%)
cTNM stage
0.475
I
5 (4.3%)
8 (8.0%)
II
37 (32.2%)
28 (28.0%)
III
73 (63.5%)
64 (64.0%)
ypTNM stage
0.917
0
1 (0.9%)
2 (2.0%)
I
7 (6.1%)
10 (10.0%)
II
11 (9.6%)
12 (12.0%)
III
13 (11.3%)
20 (20.0%)
Neoadjuvant radiotherapy
22 (19.1%)
28 (28.0%)
0.125
Neoadjuvant chemotherapy
32 (27.9%)
36 (36.0%)
0.199
Tumor location (cm)
5.97 ± 2.12
5.52 ± 2.12
0.127
Albumin(g/L)
37.99 ± 4.03
37.79 ± 3.83
0.583
Serum creatinine(μmol/L)
70.97 ± 17.44
70.59 ± 11.14
0.854
Stoma location, right
46 (40.0%)
50 (50.0%)
0.141
Distance between stoma and ileocecal part (cm)
35.33 ± 9.36
33.07 ± 11.38
0.245
BMI, body mass index; ASA, American Society of Anesthesiologists; cTNM, clinical tumor node metastasis; ypTNM, neoadjuvant pathological tumor node metastasis.
